Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019-Reference-Cited by-同舟云学术

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Published:2020-06-29 Issue:7 Volume:72 Page:1247-1250
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Titanji Boghuma K¹,Farley Monica M¹²,Mehta Ashish³⁴,Connor-Schuler Randi⁴,Moanna Abeer¹²,Cribbs Sushma K³⁴,O’Shea Jesse¹,DeSilva Kathryn²,Chan Bonnie²,Edwards Alex⁵,Gavegnano Christina⁶,Schinazi Raymond F⁷,Marconi Vincent C¹²⁵⁷

Affiliation:

1. Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA

2. Infectious Diseases, Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA

3. Pulmonary Medicine, Atlanta Veterans Affairs Medical Center, Department of Medicine, Decatur, Georgia, USA

4. Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University, Atlanta, Georgia, USA

5. Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

6. Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA

7. Emory Vaccine Center, Emory University, Atlanta, Georgia, USA

Abstract

Abstract Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.

Funder

National Institutes of Health

Emory University Center for AIDS Research

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa879/33728316/ciaa879.pdf

Reference12 articles.

1. COVID-19: consider cytokine storm syndromes and immunosuppression;Mehta;Lancet,2020

2. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China;Ruan;Intensive Care Med,2020